May 11, 2017 - These three biotechs could be stellar buys this month.
May 09, 2017 - Gilead's M&A targets may be limited because of its sizable shareholder rewards program.
May 08, 2017 - Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.
Apr 26, 2017 - Investors may consider dropping the Zacks Rank #4 Incyte Corporation (INCY) stock, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Apr 25, 2017 - Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.
Apr 23, 2017 - Looking to buy biotech stocks? Here are 7 important things to know.
Apr 21, 2017 - NewLink Genetics intriguing IDO-inhibitors could make it a target of Gilead Sciences.
Apr 20, 2017 - Nearly 90% of this biotech's sales could be at risk within the next two years.
Apr 19, 2017 - Zacks Market Edge Highlights: Insulet, Incyte, Intuitive Surgical and Edwards Lifesciences
Apr 19, 2017 - Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.